Unique characteristics of Asians with hypertension: what is known and what can be done?
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Hypertension remains the leading modifiable risk factor for cardiovascular disease worldwide. Over the past 30 years, the prevalence of hypertension has been increasing in East and Southeast Asia to a greater extent as compared with other Western countries. Asians with hypertension have unique characteristics. This can be attributed to increased impact of obesity on Asians with hypertension, excessive salt intake and increased salt sensitivity, loss of diurnal rhythm in blood pressure and primary aldosteronism. The impact of hypertension on cardiovascular (particularly strokes) and chronic kidney disease is greater in Asians. These unique characteristics underpinned by the diverse socioeconomic backgrounds pose its own challenges in the diagnosis and management of hypertension in Asia.
Identifiants
pubmed: 38509747
doi: 10.1097/HJH.0000000000003706
pii: 00004872-990000000-00426
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Executive summary. Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva: World Health Organization; 2021. Available at: https://www.ncbi.nlm.nih.gov/books/NBK573634 [Accessed 25 November 2022]
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA 2017; 317:165–182.
Dai H, Bragazzi NL, Younis A, Zhong W, Liu X, Wu J, Grossman E. Worldwide trends in prevalence, mortality, and disability-adjusted life years for hypertensive heart disease from 1990 to 2017. Hypertension 2021; 77:1223–1233.
NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398:957–980.
Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011; 124:314–323.
Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, et al. Asia Pacific Cohort Studies Collaboration Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 2007; 25:1205–1213.
Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007; 50:991–997.
Kario K, Chia YC, Sukonthasarn A, Turana Y, Shin J, Chen CH, et al. Diversity of and initiatives for hypertension management in Asia-why we need the HOPE Asia Network. J Clin Hypertens (Greenwich) 2020; 22:331–343.
GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395:709–733.
Chen A, Zou M, Young CA, Zhu W, Chiu HC, Jin G, et al. Disease burden of chronic kidney disease due to hypertension from 1990 to 2019: a global analysis. Front Med (Lausanne) 2021; 8:690487.
Ren Y, Wang Z, Wang Q. The trend of hypertension-related chronic kidney disease from 1990 to 2019 and its predictions over 25 years: an analysis of the Global Burden of Disease Study 2019. Int Urol Nephrol 2024; 56:707–718.
Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis 2021; 77:110–121.
Kario K, Chen CH, Park S, Park CG, Hoshide S, Cheng HM, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension 2018; 71:375–382.
Dorobantu MM, Giuseppe MV, Grassi G, Voicu V. Hypertension and heart failure epidemiology, mechanisms and treatment. Switzerland: Springer Nature; 2019.
Rismiati H, Lee HY. Hypertensive heart failure in Asia. Pulse (Basel) 2021; 9:47–56.
Angeli F, Reboldi G, Verdecchia P. The 2014 hypertension guidelines: implications for patients and practitioners in Asia. Heart Asia 2015; 7:21–25.
Zheng L, Sun Z, Zhang X, Xu C, Li J, Hu D, Sun Y. Predictors of progression from prehypertension to hypertension among rural Chinese adults: results from Liaoning Province. Eur J Cardiovasc Prev Rehabil 2010; 17:217–222.
Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical challenge in Asia. Hypertens Res 2015; 38:227–236.
Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res 2020; 126:1549–1564.
Murphy C, Kanaganayagam GS, Jiang B, Chowienczyk PJ, Zbinden R, Saha M, et al. Vascular dysfunction and reduced circulating endothelial progenitor cells in young healthy UK South Asian men. Arterioscler Thromb Vasc Biol 2007; 27:936–942.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36:1953–2041.
Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global Burden of Diseases Nutrition and Chronic Diseases Expert Group Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371:624–634.
Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 2013; 3:e003733.
Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med 2021; 385:1067–1077.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75:1334–1357.
Elijovich F, Weinberger MH, Anderson CA, Appel LJ, Bursztyn M, Cook NR, et al. American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Functional Genomics and Translational Biology; and Stroke Council Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension 2016; 68:e7–e46.
Chen J. Sodium sensitivity of blood pressure in Chinese populations. Curr Hypertens Rep 2010; 12:127–134.
Liu Y, Shi M, Dolan J, He J. Sodium sensitivity of blood pressure in Chinese populations. J Hum Hypertens 2020; 34:94–107.
Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37 (2 pt 2):429–432.
Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24:1164–1180.
Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas JR, et al. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. Hypertension 2015; 66:750–756.
Wang JG, Kario K, Park JB, Chen CH. Morning blood pressure monitoring in the management of hypertension. J Hypertens 2017; 35:1554–1563.
Kario K. Nocturnal hypertension: new technology and evidence. Hypertension 2018; 7:997–1009.
Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res 2012; 35:695–701.
Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res 2010; 33:515–520.
Franklin SS, Thijs L, Asayama K, Li Y, Hansen TW, Boggia J, et al. IDACO Investigators The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol 2016; 68:2033–2043.
Kario K, Thijs L, Staessen JA. Blood pressure measurement and treatment decisions. Circ Res 2019; 124:990–1008.
Angeli F, Reboldi G, Verdecchia P. Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens 2010; 23:941–948.
Fujiwara T, Yano Y, Hoshide S, Kanegae H, Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese General Practice Population. JAMA Cardiol 2018; 3:583–590.
Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854–2859.
Yoon M, Hong N, Ha J, Lee CJ, Ku CR, Rhee Y, Park S. Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. Hypertens Res 2022; 45:1418–1429.
Xu Z, Yang J, Hu J, Song Y, He W, Luo T, et al. Chongqing Primary Aldosteronism Study (CONPASS) Group Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol 2020; 7:1913–1922.
Hu Y, Zhang J, Liu W, Su X. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension. J Clin Endocrinol Metab 2020; 105:dgz293.
Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69:1811–1820.
Durand C, Vasciuc TC, Tai CH, Orpean R, Eatock F, Mahipal M, et al. Hypertension cure and reducing pill burden after adrenalectomy for endocrine hypertension of adrenal origin: a comparative study from an Asian and UK Cohort. World J Endoc Surg 2021; 13:9–15.
Puar TH, Cheong CK, Foo RSY, Saffari SE, Tu TM, Chee MR, et al. Treatment of primary aldosteronism and reversal of renin suppression improves left ventricular systolic function. Front Endocrinol (Lausanne) 2022; 13:916744.
Ohno Y, Sone M, Inagaki N, Kawashima A, Takeda Y, Yoneda T, et al. JPAS/JRAS Study Group Nadir aldosterone levels after confirmatory tests are correlated with left ventricular hypertrophy in primary aldosteronism. Hypertension 2020; 75:1475–1482.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269–1324.
Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, et al. SPRINT Research Group Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 2021; 384:1921–1930.
Blood Pressure Lowering Treatment Trialists’ Collaboration Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021; 398:1053–1064.
Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021; 385:1268–1279.
Li J, Liu J. the ESPRIT Collaborative Group Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events [Abstract]. Circulation 2023; 148:e282–e317.
Chia YC, Kario K, Turana Y, Nailes J, Tay JC, Siddique S, et al. Target blood pressure and control status in Asia. J Clin Hypertens (Greenwich) 2020; 22:344–350.
Chia YC, Buranakitjaroen P, Chen CH, Divinagracia R, Hoshide S, Park S, et al. HOPE Asia Network Current status of home blood pressure monitoring in Asia: statement from the HOPE Asia Network. J Clin Hypertens (Greenwich) 2017; 19:1192–1201.
Chan GC, Teo BW, Tay JC, Chen CH, Cheng HM, Wang TD, et al. Hypertension in a multiethnic Asian population of Singapore. J Clin Hypertens (Greenwich) 2021; 2:522–528.
Wei J, Mi Y, Li Y, Xin B, Wang Y. Factors associated with awareness, treatment and control of hypertension among 3579 hypertensive adults in China: data from the China Health and Nutrition Survey. BMC Public Health 2021; 21:423.
Mahmood S, Jalal Z, Hadi MA, Khan TM, Haque MS, Shah KU. Prevalence of nonadherence to antihypertensive medication in Asia: a systematic review and meta-analysis. Int J Clin Pharm 2021; 43:486–501.
Wang L, Li J. Role of educational intervention in the management of comorbid depression and hypertension. Blood Press 2003; 12:198–202.
Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract 2005; 55:875–882.
Wang JG, Kario K, Lau T, Wei YQ, Park CG, Kim CH, et al. Asian Pacific Heart Association Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. Hypertens Res 2011; 34:423–430.
Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160:211–220.
Kario K, Tomitani N, Kanegae H, Ishii H, Uchiyama K, Yamagiwa K, et al. Comparative effects of an angiotensin II receptor blocker (ARB)/diuretic vs. ARB/calcium-channel blocker combination on uncontrolled nocturnal hypertension evaluated by information and communication technology-based nocturnal home blood pressure monitoring - the NOCTURNE Study. Circ J 2017; 81:948–957.
Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, et al. ASCOT Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens 2010; 23:1023–1030.
Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10:499–509.
Chia YC, Turana Y, Sukonthasarn A, Zhang Y, Shin J, Cheng HM, et al. Hypertension Cardiovascular Outcome Prevention, Evidence (HOPE) Asia Network Comparison of guidelines for the management of hypertension: similarities and differences between international and Asian countries; perspectives from HOPE-Asia Network. J Clin Hypertens (Greenwich) 2021; 23:422–434.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 2019; 42:1235–1481.
Bu P, Lu X, Shi L, Feng Y, Liu L, Liu M, et al. Chinese expert recommendations on the clinical use of sacubitril-valsartan in patients with hypertension. Chin J Hypertens 2021; 29:108–114.
Lin DS, Wang TD, Buranakitjaroen P, Chen CH, Cheng HM, Chia YC, et al. HOPE Asia Network Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens (Greenwich) 2021; 23:556–567.
Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (≥65 years) with systolic hypertension. Am J Hypertens 2017; 30:1163–1169.
Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J 2021; 42:3741–3752.
Duggan S. Esaxerenone: first global approval. Drugs 2019; 79:477–481.
Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res 2019; 42:1932–1941.
Kandzari DE. Catheter-based renal denervation therapy: evolution of evidence and future directions. Circ Cardiovasc Interv 2021; 14:e011130.
Kario K, Yamamoto E, Tomita H, Okura T, Saito S, Ueno T, et al. Sufficient and persistent blood pressure reduction in the final long-term results from SYMPLICITY HTN-Japan - safety and efficacy of renal denervation at 3 years. Circ J 2019; 83:622–629.
Kim BK, Böhm M, Mahfoud F, Mancia G, Park S, Hong MK, et al. Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). J Hum Hypertens 2016; 30:315–321.
Lee CK, Wang TD, Lee YH, Fahy M, Lee CH, Sung SH, et al. Efficacy and safety of renal denervation for patients with uncontrolled hypertension in Taiwan: 3-year results from the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan). Acta Cardiol Sin 2019; 35:618–626.
Kario K, Wang TD. Perspectives of renal denervation from hypertension to heart failure in Asia. Hypertens Res 2022; 45:193–197.
Kario K, Kim BK, Aoki J, Wong AY, Lee YH, Wongpraparut N, et al. Renal denervation in Asia: consensus statement of the Asia Renal Denervation Consortium. Hypertension 2020; 75:590–602.
Kario K. The HOPE Asia Network activity for ‘zero’ cardiovascular events in Asia: overview 2020. J Clin Hypertens (Greenwich) 2020; 22:321–330.
Safar ME, Struijker-Boudier HA. Nouveaux objectifs dans la prise en charge de l’hypertension: au-delà de l’abaissement de la pression artérielle, la protection des organes-cibles [New goals in hypertension management: target-organ protection beyond blood pressure lowering]. Drugs 2003; 63:45–47.
Goh VJ, Le TT, Bryant J, Wong JI, Su B, Lee CH, et al. Novel index of maladaptive myocardial remodeling in hypertension. Circ Cardiovasc Imaging 2017; 10:e006840.
Le TT, Lim V, Ibrahim R, Teo MT, Bryant J, Ang B, et al. The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy. Eur Heart J Cardiovasc Imaging 2021; 22:670–679.
Lee V, Zheng Q, Toh DF, Pua CJ, Bryant JA, Lee CH, et al. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. Front Cardiovasc Med 2023; 10:1248468.
Iyer NR, Le TT, Kui MSL, Tang HC, Chin CT, Phua SK, et al. Markers of focal and diffuse nonischemic myocardial fibrosis are associated with adverse cardiac remodeling and prognosis in patients with hypertension: the REMODEL Study. Hypertension 2022; 79:1804–1813.